EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir–Ritonavir for COVID-19 in an interdisciplinary community clinic

Valerie Leung iD, Suzanne Gill, Andrea Llanes, Armughan Khawaja, Amanda Stagg, Janine McCready, Mariana Jacubovich, Grace Ho, Jeff Powis, Christopher Kandel

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0293302 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift PLOS ONE, 2023. Verfasst von Valerie Leung und 9 weiteren Autor:innen. Beteiligte Einrichtung: Michael Garron Hospital, Toronto East Health Network, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: COVID-19, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: TD Community Health Solutions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Large observational studies have demonstrated the real-world effectiveness of nirmatrelvir–ritonavir in preventing severe COVID-19 in higher risk individuals, but have provided limited information on other aspects of nirmatrelvir-ritonavir use. Our objective was to evaluate prescribing outcomes such as the prevalence of drug-drug interactions (DDI), adverse drug events (ADE) and treatment adherence in an outpatient community clinic setting.

Methods

We conducted a single-centre retrospective cohort study of adult outpatients prescribed nirmatrelvir–ritonavir in our community COVID-19 assessment clinic in Toronto, Ontario between March 3 and September 20, 2022. We performed a descriptive analysis of the patient population, DDIs, DDI interventions, treatment adherence, ADEs and clinical outcomes of patients prescribed nirmatrelvir–ritonavir.

Results

There were 637 individuals prescribed nirmatrelvir–ritonavir during the study period. The median age was 70, the median number of risk factors for severe disease were 2, 45% were immunocompromised and 82% had received 3 or more COVID-19 vaccine doses. 95% (542/572) completed the 5-day course of therapy with 68% (388/572) having complete symptom resolution by 28-day. Eleven percent (60/572) experienced recurrent symptoms following the completion of nirmatrelvir–ritonavir. Over 70% had one or more clinically significant DDIs requiring mitigation and 62% of patients experienced at least one ADE, which was most commonly dysgeusia or gastrointestinal-related. Ninety-five percent (542/572) of patients completed therapy as prescribed. Overall, hospitalization within 28 days was 3.3% with 1.2% attributed to COVID-19 and there were no deaths.

Interpretation

Nirmatrelvir–ritonavir was associated with a high prevalence of clinically significant DDIs, which required mitigation strategies and a high frequency of mild ADEs. Collaborative assessment to address medication alterations resulted in high treatment adherence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Drug-Related Side Effects and Adverse ReactionsAdultHumansAgedOutpatientsCOVID-19 VaccinesRetrospective StudiesRitonavirCOVID-19 Drug TreatmentDidanosineAntiviral AgentsLactamsLeucineNitrilesProline

Substanzen

COVID-19 VaccinesRitonavirDidanosineAntiviral AgentsnirmatrelvirLactamsLeucineNitrilesProline

Autor:innen und Institutionen

  • Michael Garron Hospital, Toronto East Health Network, Toronto, Ontario, Canada.
  • Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Valerie Leung

Förderung

  • TD Community Health Solutions

Zitieren

APA

Leung, V., Gill, S., Llanes, A., Khawaja, A., Stagg, A., McCready, J., Jacubovich, M., Ho, G., Powis, J., & Kandel, C. (2023). A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir–Ritonavir for COVID-19 in an interdisciplinary community clinic. PLOS ONE. https://doi.org/10.1371/journal.pone.0293302

Vancouver

Leung V, Gill S, Llanes A, Khawaja A, Stagg A, McCready J, et al. A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir–Ritonavir for COVID-19 in an interdisciplinary community clinic. PLOS ONE. 2023. doi:10.1371/journal.pone.0293302

BibTeX
@article{Leung2023,
  author = {Leung, Valerie and Gill, Suzanne and Llanes, Andrea and Khawaja, Armughan and Stagg, Amanda and McCready, Janine and Jacubovich, Mariana and Ho, Grace and Powis, Jeff and Kandel, Christopher},
  title = {A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir–Ritonavir for COVID-19 in an interdisciplinary community clinic},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0293302}
}
Kostenlos starten →